Navigation Links
Eiger BioPharmaceuticals Raises $7.1 Million 'A' Round
Date:2/24/2009

PALO ALTO, Calif., Feb. 24 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a start-up biotechnology company developing antiviral therapies, announced that it has raised $7.1 million in a Series A financing co-led by InterWest Partners and Vivo Ventures. The two firms were instrumental in the formation of the company and recruitment of its team and are represented on the board of directors by general partners Nina Kjellson and Dr. Edgar Engelman, respectively. The funding will advance the company's lead program targeted against NS4B, a specific region in the hepatitis C virus (HCV) protein, as well as progress lead identification for other proprietary targets.

Eiger is led by President and Chief Executive Officer David Cory, RPh, MBA, whose background spans over 20 years in large pharma, biotechnology, and specialty pharma with an established track record of commercial success, financial transactions, business development, and management experience. "We believe that disrupting the normal function of NS4B and NS5A proteins will lead to uniquely effective hepatitis C treatments," said David Cory, President and CEO of Eiger. "Our mission is to advance these novel small molecules into the clinic rapidly for the benefit of patients."

Eiger was founded on research conducted by Stanford professor Jeffrey Glenn, MD, PhD, whose recent research focuses on specific regions of HCV proteins NS4B and NS5A required for viral replication. "The unmet medical need in HCV treatment is significant," said Dr. Glenn. "Developing small molecule drugs and drug combinations against new HCV targets could change the HCV treatment paradigm and combat the emergence of drug resistance to new HCV polymerase and protease inhibitors." Dr. Glenn is Associate Professor of Medicine, Gastroenterology & Hepatology, Stanford University and Director of the Center for Hepatitis and Liver Tissue Engineering; he wi
'/>"/>

SOURCE Eiger BioPharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors
2. Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss
3. Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
4. XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
5. XTL Biopharmaceuticals Announces Receipt of NASDAQ Notice of Delisting
6. XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives
7. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
8. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
9. XTL Biopharmaceuticals Implements Restructuring Plan
10. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
11. Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... ... supplier, announces the launch of their 2nd generation cell therapy POD® design. The ... CT, but it also represents a new POD® design. , “G-CON first ...
(Date:7/29/2015)... , July 29, 2015  Therapath Neuropathology ( ... increased partnerships with VA and Military Medical centers ... Fiber Density (ENFD) and Sweat Gland Nerve Fiber ... neuropathy ( https://therapath.com/skin ). Demonstration ... Density (ENFD) on punch skin biopsy is a ...
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... medicine company, is pleased to announce that the final ... have been locked.  Prototypes for industrial and regulatory ... an application for CE mark clearance to market ... in 2016. (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel, a nighttime-specific product that targets ... amount of sugars that are able to enter fat cells, inhibiting the formation ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3Neuropathology services for VA and Military health systems 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3
... For 65 years, Mission Pharmacal Company has remained ... to provide the highest quality healthcare medications and treatments ... to be uncertain, this Texas-based company remains steadfast in ... to search for more and better prescription and consumer ...
... Fuels, Inc., (Pink Sheets: HRID ) announced ... CEO and President.  Mr. Cadena was the founder and ... Solutions, and will be instrumental in implementing the Company,s ... Mr. Cadena has over 25 years of extensive ...
... Md., Dec. 6, 2011 GenVec, Inc. (Nasdaq: ... the second milestone in its collaboration with Novartis (NYSE: ... treatments for hearing loss and balance disorders. The milestone ... development activities. "Completing this milestone reflects ...
Cached Biology Technology:Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive 2Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive 3Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive 4Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive 5Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive 6Hybrid Fuels, Inc. Appoints Industry Expert as New CEO 2GenVec Achieves Second Milestone in Collaboration 2GenVec Achieves Second Milestone in Collaboration 3
(Date:7/7/2015)... 2015 Research and ... of the "Capacitive Fingerprint Sensors Patent Landscape" ... this date, fingerprint sensing technology is the most ... are well developed. This patent landscape focuses on ... The domain of capacitive fingerprint sensors is closely ...
(Date:7/2/2015)... 2015 Fingerprint Cards has received an ... FPC1155 from the distributor World Peace Industrial Group (WPI), part ... Asia . Deliveries are planned to take ... used by smartphone manufacturers in Asia . ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
Breaking Biology News(10 mins):Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
... new type of electrical generator uses bacterial spores to ... research conducted at the Wyss Institute of Biologically Inspired ... driven by changes in humidity from sun-warmed ponds and ... movement of a sheet of rubber coated on one ...
... study by Yale School of Medicine researchers provides insight into ... know about reproductive health. Published in the Jan. 27 issue ... about 50% of reproductive-age women had never discussed their reproductive ... reproductive health provider less than once a year or never. ...
... January 27, 2014 Cancer is the leading ... about 30% of all deaths, according to the Canadian ... effective drugs, it remains extremely difficult to develop anti-cancer ... at how to leverage current experimental therapies, in different ...
Cached Biology News:Getting a charge from changes in humidity 2Getting a charge from changes in humidity 3The science of baby-making still a mystery for many women 2Ottawa researchers discover new combination therapy to kill cancer 2
Rab GDP dissociation inhibitor beta...
... 500V Programmable Power Supply are high-performance, ... handle virtually any application from high ... It is unique in offering both ... POWER Programmable Power Supply is completely ...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
Coating : Poly-D-Lysine ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vol working : 2.5-3.0 ml ...
Biology Products: